An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
1 other identifier
expanded_access
N/A
1 country
33
Brief Summary
To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
33 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 8, 2017
CompletedFirst Posted
Study publicly available on registry
May 10, 2017
CompletedJune 7, 2022
June 1, 2022
May 8, 2017
June 6, 2022
Conditions
Keywords
Interventions
Ruxolitinib starting dose level 10 mg orally, twice daily (BID).
Eligibility Criteria
You may qualify if:
- Male or female, 12 years of age or older.
- Have undergone an allo-HSCT from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies. Recipients of nonmyeloablative and myeloablative conditioning regimens are eligible.
- Clinically suspected all grades chronic GVHD according to NIH Consensus Criteria that is refractory or intolerant to corticosteroids, occurring after allo-HSCT with any conditioning regimen and any anti-GVHD prophylactic regimen. Clinical suspicion of steroid-refractory chronic GVHD by the treating physician is also sufficient.
- Evidence of myeloid engraftment (eg, absolute neutrophil count ≥ 1.0 × 10\^9/L for 3 consecutive days if ablative therapy was previously used). Use of growth factor supplementation is allowed.
- Evidence of platelet engraftment (ie, platelets ≥ 20 × 10\^9/L).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 3.
- Be willing to avoid pregnancy or fathering children based on 1 of the following criteria:
- Women of non-childbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea).
- Woman of childbearing potential who has a negative serum pregnancy test at screening and who agrees to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the patient and their understanding confirmed.
- Man who agrees to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through safety follow-up. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the patient and their understanding confirmed.
- Able to provide written informed consent and/or assent from the patient, parent, or guardian.
You may not qualify if:
- Eligible for an existing and actively enrolling Incyte sponsored clinical trial for ruxolitinib for the treatment of GVHD.
- Clinically suspected all grades of acute GVHD as per Minnesota-Center for International Blood and Marrow Transplant Research (MN-CIBMTR) criteria or clinical suspicion of acute GVHD by the treating physician.
- Patients or legal guardians unable to review and sign informed consent form.
- Females who are pregnant or breastfeeding, and males and females who cannot comply with requirements to avoid fathering a child or becoming pregnant.
- Patients with inadequate liver function (alanine aminotransferase above 4 × upper limit of normal (ULN) or direct bilirubin 4 × ULN and the laboratory abnormalities are considered to be due to underlying liver dysfunction) unless attributed to GVHD.
- Patients with end stage renal function (creatinine clearance (CrCl) \< 15 mL/min or glomerular filtration rate \< 15 mL/min), regardless of whether hemodialysis is required.
- Any underlying or current medical or psychiatric condition that, in the opinion of the treating physician, would place the patient at an unacceptable risk if he or she were to participate in the program.
- Previous allergic reactions to Janus kinase (JAK) inhibitors or excipients.
- Patients who are currently taking any anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, or tumor embolization).
- Concomitant use of any JAK inhibitor.
- Initiating therapy with any investigational medication.
- Presence of an active uncontrolled infection. An active uncontrolled infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection. Persisting fever without signs or symptoms will not be interpreted as an active uncontrolled infection.
- Known HIV infection.
- Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or at risk for HBV reactivation. At risk for HBV reactivation is defined as hepatitis B surface antigen positive or anti-hepatitis B core antibody positive. Previous test results obtained as part of standard of care before allo-HSCT that confirm a patient is immune and not at risk for reactivation (ie, hepatitis B surface antigen negative, surface antibody positive) may be used for purposes of eligibility.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (33)
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
Cancer Transplant Institute at HonorHealth
Scottsdale, Arizona, 85258, United States
City of Hope Medical Center
Duarte, California, 91010, United States
Scripps Clinic
La Jolla, California, 92037, United States
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
Nicklaus Children's Hospital
Miami, Florida, 33155, United States
Blood & Marrow Transplant Center
Orlando, Florida, 32804, United States
Northwestern Memorial Hospital
Chicago, Illinois, 60611, United States
University of Illinois Chicago
Chicago, Illinois, 60612, United States
Indiana Blood and Marrow Transplantation
Indianapolis, Indiana, 46237, United States
Cancer Center of Kansas
Wichita, Kansas, 67214, United States
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-5271, United States
Spectrum Health
Grand Rapids, Michigan, 49503, United States
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Rutgers Cancer Institute
New Brunswick, New Jersey, 08903, United States
New Mexico Cancer Center
Albuquerque, New Mexico, 87109, United States
Weill Cornell Medical College
New York, New York, 10021, United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Cleveland Clinic
Cleveland, Ohio, 44195, United States
Ohio State University
Columbus, Ohio, 43210, United States
Oregon Health & Science University
Portland, Oregon, 97239, United States
Gettysburg Cancer Center
Gettysburg, Pennsylvania, 17325, United States
Allegheny Health Network Cancer Institute
Pittsburgh, Pennsylvania, 15224, United States
Greenville Health System Cancer Institute
Greenville, South Carolina, 29615, United States
Avera Research Institute
Sioux Falls, South Dakota, 57105, United States
Texas Oncology
Dallas, Texas, 75246, United States
Houston Methodist
Houston, Texas, 77030, United States
Methodist Hospital
San Antonio, Texas, 78229, United States
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109-1024, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
John Galvin, MD
Incyte Corporation
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 8, 2017
First Posted
May 10, 2017
Last Updated
June 7, 2022
Record last verified: 2022-06